New partnership accelerates NHS patients’ access to new medicines and will see UK benefit from higher life sciences trade funding
- NHS patients will get improved access to life-changing remedies on account of medicines pricing changes — 2 new most cancers medicines already really helpful below the up to date strategy
- The UK is the primary nation on this planet to safe dedication to 0% tariffs on pharmaceutical exports to the US
- In a lift to financial progress, the UK will benefit from higher life sciences trade funding and extremely expert manufacturing jobs will likely be safeguarded
Thousands of NHS patients will get improved access to life-changing remedies, after the federal government agreed the full textual content of its landmark US-UK pharmaceutical partnership.
UK pharmaceutical exports to the US — price a minimum of £5 billion a yr — will enter the United States fully tariff free, for a minimum of 3 years. This makes the UK the primary nation on this planet to safe 0% tariffs on pharmaceutical exports to the US.
The partnership additionally accelerates NHS patients’ access to new medicines. Under the partnership, pharmaceutical firms have stronger incentives to launch progressive remedies within the UK, that means patients can benefit from new most cancers therapies, uncommon illness remedies, and different breakthrough medicines sooner — with out ready years after they turn into accessible elsewhere.
The partnership is a win for British patients, British businesses and the British financial system. First introduced in December, the partnership protects a UK pharmaceutical trade that added £28.5 billion to the UK financial system in 2025, employs over 50,000 individuals in extremely expert, well-paid jobs, and exported virtually £21 billion in pharmaceutical merchandise worldwide final yr.
UK Science Minister Lord Vallance stated:
Thanks to this partnership, patients proper throughout the NHS will benefit from access to life altering new medicines that they beforehand would have been denied.
Not solely this, however as the primary nation on this planet to benefit from a zero p.c tariff on prescribed drugs to the US, Britain’s life sciences sector will likely be additional boosted.
By encouraging higher funding, this partnership will allow new medicines to be developed within the UK, serving to extra individuals to reside more healthy, longer lives, whereas creating high-skilled jobs throughout the UK.
On 31 March 2026, changes have been made to the best way that the National Institute for Health and Care Excellence (NICE) evaluates medicines, because of this some remedies that ship vital well being enhancements however may beforehand have been turned down on price grounds alone, will now be accepted.
These changes reply straight to longstanding calls from affected person teams, recognising that the cost-effectiveness threshold NICE makes use of has not been up to date in over 2 many years. The up to date threshold will subsequently be sure that NICE is ready to proceed its world main strategy to assessing medication and remedies, reflecting the massive changes within the financial, business and healthcare setting that we function in.
The replace to the NICE price effectiveness threshold has already made a direct distinction for NHS patients. Two medicines have already been really helpful by NICE below the brand new threshold, giving patients quick accessing to life-changing medicines — together with a mind most cancers drug for patients as younger as 12 and a last-resort therapy for patients with a uncommon type of abdomen most cancers who had already exhausted different choices. NHS patients in England will likely be in a position to access these by the well being service, thanks to the brand new thresholds.
Dr Karen Noble, Director of Research, Policy and Innovation at Brain Tumour Research, stated:
The announcement that NHS patients will achieve improved access to life-changing remedies on account of the medicines pricing change is a welcome step ahead for the mind tumour group. We are already seeing the affect of this shift, with vorasidenib – the primary new therapy for grownup mind tumours within the UK for 2 many years – now accessible to eligible patients on the NHS. We are hopeful that this can unlock additional progressive remedies and guarantee extra promising medication clear the edge for approval, opening up new alternatives and higher outcomes for mind tumour patients.
Crucially, improved access alone is just not sufficient, and we should be sure that these new medicines are coming throughout the pipeline. Increased funding in analysis stays crucial to accelerating the invention and improvement of remedies for mind tumours, and we are going to proceed to marketing campaign for this on behalf of our group.
Cathy Hampshire, Vice-Chair of GIST Cancer UK who has lived with GIST most cancers for 5 years, stated:
Regorafenib has a restricted window of effectiveness. At each scan and each session, I brace myself for the second I’m informed the drug has stopped working, that the tumours are rising once more, and that there isn’t any additional therapy choices left.
This UK-US pharmaceutical partnership and NICE’s resolution to approve the therapy changes that image totally. I used to be actually dancing across the room after I heard. When you’re on the third of the three accessible remedies and been informed there are not any extra choices, you’re feeling just like the system has given up on you. After a two-year battle, the UK authorities by this partnership and NICE has recognised the significance of constructing Ripretinib accessible. For individuals like me throughout England and Wales, this opens up a brand new therapy pathway — and with it, renewed hope. I really feel as if an enormous weight has lifted from my shoulders. For the primary time in an extended whereas, there’s gentle on the finish of the tunnel.
The UK has now additionally secured preferential phrases for medical know-how exports, with no further new tariffs on medtech for a minimum of 3 years — unlocking additional funding in British manufacturing and strengthening the UK’s place as a world chief in well being innovation.
The medtech sector employs over 195,000 individuals throughout the UK, and these preferential phrases present businesses with the knowledge they want to make investments, develop, and create jobs right here.
The UK and US have additionally agreed to work collectively in the direction of mutual recognition of medical machine approvals — chopping crimson tape and supporting future progressive well being applied sciences to attain patients on either side of the Atlantic.
In addition, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) headline cost proportion — the rebate pharmaceutical firms pay on branded medicines bought to the NHS — will likely be capped at a most of 15% till the tip of the present scheme, which expires on 31 December 2028, offering the soundness and predictability that life sciences firms want to make investments and develop within the UK.
Dr Zubir Ahmed, Health Innovation and Safety Minister, stated:
For too lengthy, NHS patients have watched as some remedies accessible in different nations remained out of attain right here. We’re altering that.
From April, 1000’s of individuals throughout the UK will likely be in a position to access remedies on the NHS that have been beforehand out of attain. This is the primary time in over twenty years that we have now raised the bar for what the NICE can approve, and it means life-changing medicines can attain the patients who want them most.
This authorities made a dedication to make the NHS match for the long run — and we’re delivering on it by constructing an NHS that works higher for patients, alongside with constructing an financial system that delivers expert jobs and progress throughout the nation.
To drive additional progress, the federal government and the UK life sciences trade have launched a brand new Joint Taskforce to speed up innovation within the UK’s business setting for medicines. It will report again to ministers and trade leaders with preliminary findings, with pilot schemes anticipated to launch as early as September 2026.
The Taskforce will work with the pharmaceutical sector, NHS England, NICE, and affected person and charity teams, to assist the UK turn into the third most vital life sciences financial system by 2035—as outlined within the 10 Year Health Plan and Life Sciences Sector Plan.
The authorities has dedicated to doubling spending on progressive medicines as a proportion of GDP — from 0.3% to 0.6% over the subsequent 10 years. This means NHS patients get wider and quicker access to the remedies they want, together with for most cancers and different life-limiting situations.
It additionally sends a transparent sign to international traders that the UK is a severe, long-term companion for the life sciences trade — supporting financial progress and high-skilled jobs throughout the nation.
Chris Boerner, Bristol Myers Squibb Board Chair and CEO, stated:
Bristol Myers Squibb welcomes this association as a step towards correctly recognising the worth of progressive medicines so patients within the UK can access them sooner. We will work with the UK and US governments to help this objective and recognise the Prime Minister’s deal with constructing a greater medicines ecosystem. We are pleased with our UK websites and their function in delivering for patients and anticipate investing greater than $500 million within the UK over the subsequent 5 years.
Richard Torbett, Chief Executive of the ABPI, stated:
This landmark partnership is an vital step ahead for patients, the NHS and the UK’s life sciences sector. It reinforces the UK’s place as a world centre for innovation, serving to to entice funding and speed up access to cutting-edge medicines.
The authorities has listened to trade issues and is taking constructive motion to enhance access and create a extra secure, aggressive setting. While additional element and technical work is underway, that is robust progress, and we glance ahead to working carefully with the federal government to guarantee these commitments ship for patients, the NHS and the UK financial system.
As a part of the UK’s ambition to be the main Life Sciences Economy in Europe by 2030 and to maximise the financial advantages of those changes, we will likely be working carefully with trade to assist land funding into the UK.
The partnership will help higher funding in UK life sciences. It has already began producing outcomes, resembling £500 million investment in UK R&D and manufacturing in Surrey from the global biopharmaceutical company UCB which was announced in January, turbocharging financial progress.
Business and Trade Secretary Peter Kyle stated:
This authorities’s commerce technique is delivering for our world-leading pharma sector, accelerating well being innovation whereas defending high-skilled jobs right here within the UK.
Partnerships like this exhibit the tangible advantages of our robust UK-US financial relationship, and we are going to proceed to prioritise getting the perfect for British enterprise by the Economic Prosperity Deal.
This finalised textual content builds on the General Terms of the UK-US Economic Prosperity Deal signed in May and takes ahead commitments made when the rules of this partnership have been first introduced in December.
The partnership varieties a part of the federal government’s Life Sciences Sector Plan, backed by over £2 billion of funding, and its Modern Industrial Strategy
Further quotes:
Shay Emerton was recognized with a grade 2 glioma, a sort of mind tumour, on the age of 24. Shay has been in a position to access the drug Vorasidenib, which has had a major affect on high quality of life. However, this access had beforehand been below menace. The new partnership will now assist be sure that patients like Shay can benefit from these life‑altering remedies. Shay stated:
I take into account myself extraordinarily fortunate to have accessed Vorasidenib on the managed access scheme. It actually has modified my life considerably and this resolution from NICE is a recreation changer in neurooncology. It was an honour to be the affected person advocate on the NICE appraisal as I used to be in a position to signify the low grade glioma group who might benefit from this drug. It has now given not solely me however hopefully many patients across the UK hope for the long run and ultimately one other choice in contrast to the usual therapy of care. I hope that is simply the beginning of the a lot wanted enchancment in care choices for low grade glioma patients.
Dave Ricks, Chair & CEO of Eli Lilly and Company, stated:
This UK / US association on prescribed drugs is an encouraging transfer; the constructive development within the UK warrants our consideration and Lilly will revisit our funding plans there because the setting improves.
A spokesperson from GSK, stated:
We are happy that the partnership between the UK and US on prescribed drugs has been finalised. It offers certainty on zero-tariffs for medicines and gives actual enhancements to the UK working setting and rewards for innovation.
This is a vital basis for the UK’s international competitiveness in life sciences and for future funding within the nation. As a longstanding and vital investor within the UK, GSK is especially inspired by the commitments contained within the partnership.
Work now wants to occur at tempo on the detailed actions to ship these enhancements and GSK is dedicated to supporting this.
Dr Scott Purdon, Chair of the Charity Medicines Access Coalition (CMAC) and Head of Patient Advocacy at Myeloma UK, stated:
Investment within the UK life sciences sector and improved access to medicines is welcome information. The approval of two new most cancers remedies, enabled by changes to the NICE thresholds, gives actual hope to individuals ready for new choices. For many patients and their households, these choices can imply extra time and a greater high quality of life.
We hope this marks the start of many extra approvals. Continued funding in analysis and innovation is crucial to delivering the breakthrough remedies patients urgently want. This announcement is a welcome step, however only one piece of a a lot greater image.
What issues now could be seeing a real and lengthy‑time period dedication from the pharmaceutical trade to spend money on UK analysis and improvement. That means increasing scientific trial alternatives for individuals throughout the UK and reinforcing the UK’s status as a world chief in science and well timed access to medicines.
We look ahead to working carefully with DHSC so that individuals can meaningfully access these progressive remedies. Ultimately, each resolution ought to carry us nearer to what issues most: quicker, fairer access to life‑altering remedies for the individuals who want them.
Nicola Perrin, Chief Executive of the Association of Medical Research Charities, stated:
For our member charities, the worst potential situation is having a discovery caught within the lab, or a therapy accessible in different nations however not by the NHS. We subsequently welcome this announcement and the progress that has been made since final December. This reinforces the federal government’s dedication to making the UK top-of-the-line locations on this planet to develop new remedies. It will even assist to be sure that patients can access new medicines as shortly as potential.
Dr Ian Walker, Executive Director of Policy at Cancer Research UK, stated:
Research into kinder, more practical and extra focused remedies depends on the UK sustaining its world-leading place within the life sciences sector. These changes to the best way that NICE evaluates new medicines will lead to higher funding within the trade, critically enabling extra life-saving discoveries for individuals with most cancers and making certain that patients obtain the therapy they deserve.
Changes to the pricing of medicines ought to assist to enhance patients’ access to confirmed, progressive medication, and it’s vital that that is delivered as a broader bundle of funding throughout the NHS.
Abbvie Executive Vice President and Chief Commercial Officer, Jeff Stewart stated:
We recognize the US-UK prescribed drugs association as a primary step in recognising the affect of progressive medicines on affected person outcomes. We imagine fast implementation of the partnership is now wanted to ship significant outcomes for patients and the sector.
Nico Reynders, General Manager, UCB UK & Ireland, stated:
We welcome the federal government’s dedication to bringing progressive remedies to UK patients and this association helps trade/authorities collaboration to guarantee UK residents have access to the perfect remedies throughout all illness areas.
UCB stays a dedicated, strategic companion within the UK healthcare system by funding in analysis, improvement and manufacturing of progressive medicines which we purpose to carry to UK patients concurrently with patients worldwide.
Professor Andrew Morris CBE FRSE PMedSci, President of the Academy of Medical Sciences, stated:
Getting efficient remedies to patients quicker is what issues most, and the approval of latest medicines as a direct results of these changes exhibits that this association could make an actual distinction to individuals and households.
The dedication to enhance spending on progressive medicines, backed by interim targets, is a welcome step in the direction of a system that correctly values the contribution of medical science. Planned changes to how NICE measures the affect of remedies on patients’ high quality of life will even carry its strategies into line with newest proof – one thing researchers and clinicians have lengthy known as for.
A robust life sciences sector advantages patients first and foremost by supporting quicker and fairer access to new remedies, extra scientific trials, and continued medical analysis. It may also carry wider advantages to the financial system by funding and expert jobs. But for patients to really feel the complete benefit, this should go hand in hand with broader funding within the NHS and the well being and care companies they depend on daily.